Background. Initial management of community-acquired pneumonia (CAP) has been a Centers for Medicare and Medicaid Services performance measure for a decade. We hypothesized that an intervention directed at management of CAP that assesses areas not covered by the performance measures-treatment duration and antimicrobial selection after additional microbiology data are available-would further improve CAP management.
Community-acquired pneumonia (CAP), along with influenza, was the eighth leading cause of death in the United States in 2007 [1] . The Centers for Medicare and Medicaid Services (CMS) and the Joint Commission support quality-improvement initiatives in CAP, endorsing performance measures for CAP that include blood cultures, timely antimicrobial therapy (within 6 hours after patient presentation), appropriate antimicrobial selection, smoking cessation, vaccination, and measuring mortality [2] . Consequently, hospitals have spent significant resources on ensuring that patients presenting with suspected CAP receive appropriate empirical therapy in a timely fashion. These initiatives have been successful, as evidenced by an increase in the national compliance rate up to 94.3% in 2009 [3] . On the basis of these results, the CMS recently announced that, as of 1 January 2012, the measure assessing timing of initial empirical antibiotics will be retired [4] .
The retirement of this measure will address the significant issue of clinicians starting antibiotics too rapidly in patients who may not have CAP, in order to be compliant. Misdiagnosis of CAP has been reported in 22%-46% of cases [5] [6] [7] ; thus, many patients receive potentially unnecessary antibiotics and some have adverse events while receiving this therapy. One study found an outbreak of severe Clostridium difficile infection in 12 patients treated for CAP, of whom 6 most likely did not have CAP [8] . Little emphasis has been placed on assessment of the downstream treatment of patients thought to have CAP at the time of admission, including timely cessation of antibiotics when another diagnosis is determined and the appropriate narrowing and duration of therapy in patients who have CAP. Studies have noted significant variation in clinical practice in the management of CAP across institutions [9, 10] .
We hypothesized that, despite a high compliance rate with the CAP quality measures, we likely had suboptimal management of CAP beyond the period of initial antibiotic administration. We performed a prospective, observational study, followed by an intervention to improve management of CAP, with the goals of (1) decreasing treatment duration, (2) increasing use of microbiology results to narrow therapy, and (3) decreasing duplicate therapy within 24 hours.
METHODS

Setting and Study Population
We conducted a prospective pre-and postintervention study at The Johns Hopkins Hospital, a 925-bed tertiary care facility in Baltimore, Maryland. All adults patients ($18 years) who received a diagnosis of presumed CAP and were admitted to an inpatient general medicine service from 1 January 2008 through 31 March 2008 (preintervention period) and from 1 February 2010 through 10 May 2010 (intervention period) were eligible for inclusion. Exclusion criteria included residence in a long-term care facility, diagnosis of cystic fibrosis, admission to oncology service, and admission for a lower respiratory tract infection within the previous 30 days. All patients considered to have CAP by the treating team at admission were reviewed by the Antimicrobial Stewardship Team (AST) (infectious diseases physician and pharmacist) to determine whether they had a true diagnosis of CAP, as defined by Infectious Diseases Society of America guidelines [2] . Patients who met criteria for CAP were classified as having ''final CAP,'' and patients who did not were assigned an alternative diagnosis.
Definitions
Patients were considered to be immunocompromised if they had undergone solid organ transplantation; were receiving active chemotherapy for cancer; had an immunodeficiency syndrome, including human immunodeficiency virus (HIV) infection; or were receiving active immunosuppressant therapy for other diseases (eg, long-term steroid therapy with prednisone at .10 mg/d or equivalent). Severity-of-illness scores for CAP, CURB-65 (confusion, uremia, elevated respiratory rate, low blood pressure, and age $65 years), and pneumonia severity index (PSI) were calculated for all patients [11, 12] . Duplicate therapy was defined as receipt of antibiotics with the same or similar spectrum of activity within the 24-hour period starting with receipt of the first dose of antibiotics that was not given because of desire for broadened coverage. Duration of antibiotic therapy was calculated by adding the number of days that the patient received antibiotics as an inpatient and the prescribed outpatient duration according to the discharge summary. Appropriate duration of antibiotic therapy based on patient-specific factors was used to calculate excess antibiotic therapy duration during both periods and was suggested to teams during the intervention period: 5 days for patients without immunocompromise or structural lung diseases; 7 days for patients with moderate immunocompromise and/or structural lung diseases; and 10-14 days for patients who had poor clinical response, received initial inappropriate therapy, or were significantly immunocompromised. Patients with uncomplicated bacteremic pneumococcal pneumonia were recommended to receive the same aforementioned durations of treatment. The excess number of days of antibiotic use was calculated by subtracting the appropriate duration of antibiotic therapy from the total prescribed duration.
Data Collection
Data on demographic characteristics, clinical symptoms, radiology, microbiology, and antibiotic therapy were collected prospectively throughout each patient's hospital course from the medical record. Interventions made by the AST and clinical pharmacy specialists during the intervention period were documented on a data collection form. The Johns Hopkins University Institutional Review Board approved the study with a waiver of informed consent.
Intervention
After a prospective observational study conducted in 2008 to evaluate management of CAP at our institution and identify opportunities for improvement, we developed and implemented a 3-component intervention to improve CAP therapy beyond initial empirical therapy, which included (1) a survey of medical staff to assess knowledge and practices related to the diagnosis and treatment of inpatients with CAP that was administered before the educational interventions with the goal of providing feedback regarding these issues; (2) an educational lecture presented to medical staff and hospital attending physicians, including the survey results, baseline data, and evidencebased information about duration of therapy in specific populations and short-course therapy; and (3) a prospective review of the management of patients with CAP by the antimicrobial stewardship and other clinical pharmacy specialists, with direct oral feedback regarding suggested changes.
Outcome Measures
The primary outcome was duration of antibiotic therapy. Secondary outcomes were the percentage of cases in which microbiology data were used to narrow therapy and the percentage of patients receiving duplicate therapy. Patients were excluded from the analysis of the primary outcome if they died during the study period, if they left the hospital against medical advice, if the outpatient antibiotic duration was not stated in the discharge summary, or if CAP was complicated by empyema that required drainage or was caused by Staphylococcus aureus.
Statistical Analysis
Statistical analyses were performed using Stata software (version 9; StataCorp). Comparison of 2008 and 2010 cohort variables was performed using the 2-sided t test for continuous variables, the z test for comparison of proportions, the Wilcoxon rank sum test for median comparisons of total duration of antibiotic therapy and excess duration of antibiotic therapy, and the v 2 test for ordinal and categorical variables (Fisher's exact test was used for cell values ,5). All statistical tests were 2 tailed; differences were considered statistically significant at P # .05. Figure 1 ; the most common diagnoses in both years were viral pneumonia without evidence of concomitant bacterial pneumonia. Twenty one (37%) of these patients received a course of antibiotics appropriate for non-CAP indications (eg, chronic obstructive pulmonary disease flare and non-CAP infection); 13 (23%) received antibiotic therapy empirically because of uncertainty of the initial diagnosis and discontinued therapy appropriately by day 3. However, 23 patients (40%) continued antibiotic therapy inappropriately beyond day 3, despite having an alternative diagnosis that did not require antibiotic therapy.
RESULTS
Ninety
Patient Characteristics
Patient characteristics in the final CAP group were similar in both periods, although there were more patients with alcohol abuse in the preintervention group (Table 1) . Most patients were admitted to the medical floor rather than the intensive care unit (87% in 2008 and 89% in 2010). The median PSI was 82 in both periods with an even distribution among risk classes. CURB-65 scores also were similar and were overall low, suggesting a relatively low risk of death in the cohort. The number of immunocompromised patients was similar between the 2 periods (45% in 2008 vs 38% in 2010), with a slightly higher number of HIV-infected patients in the 2008 cohort.
Microbiology
The majority of patients in the final CAP group had at $1 microbiologic specimen collected (.90%) ( Table 2 was a respiratory fluoroquinolone (moxifloxacin) in 2008 (58%) and a nonpseudomonal b-lactam (ceftriaxone) plus macrolide (azithromycin) in 2010 (58%).
Forty-eight stewardship interventions were made in 34 patients during the intervention period, with an acceptance rate of 69%. The most common recommendation was to shorten duration of antibiotic therapy (59%), followed by modification of antibiotic selection (32%) and discontinuation of unnecessary antibiotics (20%). There was a significant decrease in the incidence of changing therapy within 48 hours from the initial regimen prescribed in the emergency department to a different antibiotic regimen between the preintervention and intervention period (from 57% in 2008 to 21% in 2010), with most changes to an antibiotic of the same or a similar spectrum of activity. Fewer patients received duplicate therapy within 24 hours in the intervention period (90% in 2008 vs 55% in 2010), although of those who received duplicate therapy, more did so within 12 hours in the intervention period (34% in 2008 vs 44% in 2010).
In 2008, 21 patients (34%) had a causative pathogen identified, compared with 9 (14%) in 2010. Antibiotic therapy was narrowed or otherwise modified in 4 of 6 cases (67%) in 2010 that could have had therapy narrowed based on susceptibility results, and in 3 of 16 (19%) in 2008. In addition, patients in the intervention period were more likely to be discharged without antibiotics (26%) than were patients in the preintervention period (14%). More patients were discharged home with respiratory fluoroquinolone therapy in 2008 than in 2010 (63% vs 35%).
Fifty-six patients from the preintervention period and 63 from the intervention period were included in the analysis of duration of antibiotic therapy ( Table 3 ). The median duration of antimicrobial therapy decreased from 10 to 7 days (P , .001), leading to 148 fewer days of antibiotic therapy. During the preintervention period, the most frequent duration of therapy was 8-10 days, compared with 6-7 days during the intervention period. . Staff reported that their most commonly recommended duration of therapy was 7 days (72%); nearly one-third (29%) would not treat for ,7 days. The most common discharge antibiotic therapy in patients without culture data was a respiratory fluoroquinolone (65%), even if the patient had been treated with a cephalosporin and macrolide as an inpatient. If penicillinsusceptible S. pneumoniae grew in the sputum culture, 87% of respondents reported they would narrow treatment to an oral penicillin alone (amoxicillin [44%], penicillin VK [21%], or amoxicillin-clavulanate [22%]); however, if nonb-lactamase-producing Haemophilus influenzae grew in the sputum culture, 35% continued broad-spectrum therapy with a respiratory fluoroquinolone or third-generation cephalosporin.
DISCUSSION
Our study revealed that an educational intervention, combined with direct feedback, decreased the duration of antimicrobial .14 days 9 0
Excess antibiotic days, total, days therapy prescribed for CAP from a median of 10 days to a median of 7 days, resulting in a 61% reduction in unnecessary days of antibiotic therapy. In addition, we found a reduction in receipt of duplicate therapy within 24 hours.
Shortening the duration of antibiotic treatment for CAP can decrease overall antibiotic consumption, which is thought to be an important factor in the development of drug resistance in respiratory pathogens [13] [14] [15] [16] . A number of studies have shown that shorter courses of therapy for CAP are effective as longer courses [17] [18] [19] . Levofloxacin (750 mg for 5 days) was effective as levofloxacin (500 mg for 10 days) in patients with mild-severe CAP, with success rates of 92.4% and 91.1%, respectively, and a 3-day course of amoxicillin was as effective as an 8-day course in patients admitted to the hospital with mild to moderate-severe CAP (with a success rate of 93% in both groups) [17, 18] . Current Infectious Diseases Society of America and American Thoracic Society consensus guidelines on the management of CAP in adults recommend that patients with CAP be treated a minimum of 5 days (not 3 days) and provide a list of criteria for the transition from parenteral to oral antibiotics or antibiotic discontinuation based on demonstration of clinical improvement before cessation of antibiotics [2] .
Despite the aforementioned investigations and guidelines, most patients in the preintervention period in our study received 8-14 days of therapy. When staff were surveyed before any education intervention regarding antibiotic choice and duration, they recommended a shorter mean course of therapy than they actually gave (7 days), although one-third of respondents were uncomfortable with a course ,7 days. Even after education and a stewardship intervention, only a small proportion of patients received #5 days of therapy. This may be explained by the high proportion of HIV-infected patients in the cohort, in whom specific recommendations for length of therapy for CAP have not been defined; however, even these patients did not have a high severity of illness, as determined by the CURB-65 and PSI scores. We suspect that many clinicians who treat inpatients with pneumonia are not familiar with the studies and guidelines that support short-course therapy and feel uncomfortable using such courses.
Our study supports the CMS decision to retire the requirement that the first dose of antibiotic be administered within 6 hours, which leads to treatment of patients who do not ultimately have CAP. This occurred in 37% of patients in the 2008 cohort and 24% in the 2010 cohort, leading to inappropriate antimicrobial use in 40% of these patients. This requirement may also be a contributing factor to the observation that 90% of patients in 2008 and 55% in 2010 received excessive duplicate antibiotic therapy within 24 hours, perhaps because providers place greater emphasis on ensuring that patients have received antibiotics than on determining what has already been administered. These duplications are particularly concerning when they involve 2 doses of respiratory fluoroquinolones given in a short period, because of the risk of QT prolongations and confusion in older patients.
In addition, we observed that sputum samples were rarely obtained in the emergency department, and the majority of our patients received $1 dose of antibiotics before sputum cultures were obtained, leading to a low rate of isolation of organism from sputum. Infrequent identification of causative pathogen was observed in a recent review of 17 435 patients hospitalized with CAP for whom etiologic diagnosis was established in only 7.6% [20] . Although the yield of sputum samples is notoriously low [2, [21] [22] [23] , we found that treatment could be modified in patients with cultures in which a likely pulmonary pathogen grew or with positive results for urinary antigens. Lack of data on the causative pathogen was associated with continuing excessive broadspectrum agents for CAP and reluctance to narrow antibiotics when a pathogen was not isolated. Narrowing of antibiotics in patients with positive culture results increased by 47% during the intervention period, suggesting that, with prompting, clinicians will narrow therapy. Narrowing antimicrobial therapy and shortening its duration has the potential to minimize emergence of resistance and decrease antibiotic-related adverse effects; efforts should be made in future CAP management guidelines to address these issues.
Our study has limitations. First, data on the total duration of antibiotic therapy were composed of what patients were known to have received as inpatients and what the discharge summary stated was received as an outpatient. Patients may not have filled the prescription or taken the total course of antibiotics. Prescribers may have changed the antibiotics because of insurance issues or adverse effects. Second, the intervention period of the study occurred immediately after the H1N1 influenza pandemic, leading to a marked decrease in the numbers of patients presenting with influenza pneumonia or bacterial pneumonia after influenza. Although not apparent from our analysis, this difference may have affected rates of hospital admissions for CAP, severity of illness, type of infecting organism, and prescriber's practice behavior. Third, interventions did not occur in all patients, probably because of short hospitalization that often occurred over weekends. The duration of therapy during the intervention period may have been even shorter if we had been able to intervene with all patients. Fourth, our institution has a well-established AST, which might have been the key to the success of our interventions; therefore, the practice changes described in our study may not be attainable at smaller hospitals with limited resources and no dedicated AST.
Our study was conducted at a single center and included a small number of patients; larger studies in a variety of hospital settings are necessary to ensure generalizability of our results. Nevertheless, our findings revealed that interventions to decrease duration of antibiotic therapy for CAP can be successful. Future guidelines for management of CAP should promote the use of shorter courses of therapy, and the CMS should consider duration of therapy as a future CAP performance measure.
Notes
